Comparison of clinical characteristics and median OS of patients with IgD myeloma between major published studies
| Study . | Study population . | Median age (y) . | Male (%) . | Hb < 100 g/L (%) . | Serum creatinine > 2 mg/dL (%) . | Extramedullary involvement (%) . | Λ light chain association (%) . | Median OS (mo) . |
|---|---|---|---|---|---|---|---|---|
| Jancelewicz et al 1975 | Retrospective review of IgD myeloma cases (n = 133) | 56 | 76 | 61 | 31 | 73 | 90 | 9 |
| Shimamoto et al 1991 | Retrospective study of Japanese patients with IgD myeloma (n = 165) | 56 | 76 | 50 (Hb < 85 g/L) | 43 | 27 | 82 | 12 |
| Blade et al 1994 | Single US center report of IgD myeloma cases diagnosed 1965-1992 (n = 53) | 60 | 62 | 29 | 33 | 19 | 60 | 21 |
| Morris et al 2010 | Retrospective study of IgD myeloma cases in the EBMT myeloma database for patients undergoing autologous stem cell transplants 1986-2007 (n = 379) | 54 | 65 | ∼50 | Median 130 mmol/L (1.47 mg/dL) | — | 75 | 43.5 |
| Kim et al 2011 | Korean myeloma registry database 1997-2009 (n = 77) | 57 | 67 | 75 | 53 | 11 | 89 | 18.5 |
| Zagouri et al 2013 | Cohort study by the Greek Myeloma Study group 2000-2012 (n = 31) | 65 | 52 | 58 | 52 | — | 84 | 51.5 |
| Liu et al 2020 | Asian Myeloma Network (China, Korea, and Singapore) multicentre cohort study 2012-2019 (n = 356) | 56 | 68 | 65 | 36 | 19 | 89 | 36.5 |
| Study . | Study population . | Median age (y) . | Male (%) . | Hb < 100 g/L (%) . | Serum creatinine > 2 mg/dL (%) . | Extramedullary involvement (%) . | Λ light chain association (%) . | Median OS (mo) . |
|---|---|---|---|---|---|---|---|---|
| Jancelewicz et al 1975 | Retrospective review of IgD myeloma cases (n = 133) | 56 | 76 | 61 | 31 | 73 | 90 | 9 |
| Shimamoto et al 1991 | Retrospective study of Japanese patients with IgD myeloma (n = 165) | 56 | 76 | 50 (Hb < 85 g/L) | 43 | 27 | 82 | 12 |
| Blade et al 1994 | Single US center report of IgD myeloma cases diagnosed 1965-1992 (n = 53) | 60 | 62 | 29 | 33 | 19 | 60 | 21 |
| Morris et al 2010 | Retrospective study of IgD myeloma cases in the EBMT myeloma database for patients undergoing autologous stem cell transplants 1986-2007 (n = 379) | 54 | 65 | ∼50 | Median 130 mmol/L (1.47 mg/dL) | — | 75 | 43.5 |
| Kim et al 2011 | Korean myeloma registry database 1997-2009 (n = 77) | 57 | 67 | 75 | 53 | 11 | 89 | 18.5 |
| Zagouri et al 2013 | Cohort study by the Greek Myeloma Study group 2000-2012 (n = 31) | 65 | 52 | 58 | 52 | — | 84 | 51.5 |
| Liu et al 2020 | Asian Myeloma Network (China, Korea, and Singapore) multicentre cohort study 2012-2019 (n = 356) | 56 | 68 | 65 | 36 | 19 | 89 | 36.5 |
EBMT, European Society for Blood and Bone Marrow Transplantation; Hb, hemoglobin.